- Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosisAnders Dahm
Department of Hematology, Ulleval University Hospital, Oslo, Norway
Blood 101:4387-92. 2003..These results indicate that low levels of TFPI, especially low TFPI-free and total antigen in plasma, constitute a risk factor for DVT...
- Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal stateAnders Dahm
Department of Haematology, Ulleval University Hospital, Oslo, Norway
Br J Haematol 132:333-8. 2006..9 (1.7-20). We concluded that the effect of hormonal state on dPT was mediated through TFPI, and a dPT-based assay of TFPI anticoagulant activity did not assess the risk for DVT better than conventional TFPI assays...
- Mechanisms of thrombosis related to hormone therapyPer Morten Sandset
Oslo University Hospital at Ullevål, Department of Hematology, Oslo, Norway Faculty of Medicine, University of Oslo, Oslo, Norway
Thromb Res 123:S70-3. 2009..Coagulation markers should be used as intermediate or surrogate markers in early pharmacodynamic studies to evaluate the risk associated with new formulations...
- Decreased lung cancer survival with hormone-replacement therapy: caused by a decreased tissue factor pathway inhibitor level?Helene F S Negaard
J Clin Oncol 24:2683-4; author reply 2684. 2006